2型糖尿病胰岛素方案比较:系统综述与网络Meta分析
与基础胰岛素相比,复杂方案HbA1c降幅略优但体重增加约1 kg且严重低血糖风险呈边缘升高,证据置信度为中等,支持个体化选择方案。
要点
- 复杂胰岛素方案较基础胰岛素HbA1c降幅略优,但证据置信度中等。
- 所有方案约增加30%达标概率,但体重增加约1 kg。
- 严重低血糖风险呈边缘升高,需结合患者偏好个体化选择。
核心结论
- 复杂胰岛素方案较基础胰岛素提供适度血糖获益,但体重增加更多且严重低血糖风险可能更高。
- 证据置信度为中等,方案选择需结合临床情境、患者偏好和治疗目标进行个体化。
研究设计与样本
- 检索PubMed、EMBASE、Cochrane Library和ClinicalTrials.gov至2025年9月。
- 纳入标准为比较至少两种指定胰岛素方案且疗程≥12周的RCT,采用频率随机效应模型并以基础胰岛素为参照。
主要发现
- 较基础胰岛素,基础-餐时方案HbA1c降低-3.4 mmol/mol(95%CI -4.9, -1.9 mmol/mol;-0.31%[95%CI -0.45%, -0.17%])。
- 双相胰岛素HbA1c降低-2.7 mmol/mol(95%CI -3.7, -1.6 mmol/mol;-0.24%[95%CI -0.34%, -0.15%])。
- 餐时胰岛素HbA1c降低-4.1 mmol/mol(95%CI -6.2, -2.1 mmol/mol;-0.38%[95%CI -0.57%, -0.19%])。
- 所有方案约增加30%的HbA1c达标概率,体重增加约1 kg,严重低血糖风险呈边缘升高。
- 基础-餐时和双相方案胰岛素剂量略高,生活质量数据有限。
关键数值与推荐
- 较基础胰岛素,基础-餐时方案HbA1c降低-3.4 mmol/mol(95%CI -4.9, -1.9 mmol/mol)。
- 双相胰岛素HbA1c降低-2.7 mmol/mol(95%CI -3.7, -1.6 mmol/mol)。
- 餐时胰岛素HbA1c降低-4.1 mmol/mol(95%CI -6.2, -2.1 mmol/mol)。
- 所有方案约增加30%达标概率,体重增加约1 kg,严重低血糖风险呈边缘升高。
临床怎么用
- 复杂胰岛素方案血糖获益适度但体重增加和低血糖风险需权衡。
- 方案选择应结合临床情境、患者偏好和治疗目标个体化。
局限性
- 证据置信度为中等,因存在不一致性。
- 生活质量数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Insulin therapy is essential for managing hyperglycaemia in type 2 diabetes mellitus when oral or non-insulin injectable agents are no longer effective. However, the comparative effectiveness and safety of different insulin regimens remain uncertain. We aimed to compare the effects of basal, basal-bolus, biphasic and prandial insulin regimens on glycaemic management, weight, severe hypoglycaemia, insulin dose and quality of life in adults with type 2 diabetes. METHODS: We conducted a systematic review and network meta-analysis of RCTs. PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov were searched through to September 2025. The inclusion criteria for studies were RCTs enrolling adults with type 2 diabetes that compared at least two of the specified insulin regimens over ≥12 weeks. Pairs of reviewers independently screened studies, extracted data and assessed risk of bias using the Cochrane RoB-2 tool. Network meta-analyses were performed using a frequentist random-effects model, with basal insulin as the reference. RESULTS: Fifty-eight RCTs involving 19,122 participants were included. Compared with basal insulin, HbA1c reduction was -3.4 mmol/mol (95% CI -4.9, -1.9 mmol/mol) (-0.31% [95% CI -0.45%, -0.17%]) with a basal-bolus insulin regimen, -2.7 mmol/mol (95% CI -3.7, -1.6 mmol/mol) (-0.24% [95% CI -0.34%, -0.15%]) with biphasic insulin and -4.1 mmol/mol (95% CI -6.2, -2.1 mmol/mol) (-0.38% [95% CI -0.57%, -0.19%]) with prandial insulin. These results were classified as being of moderate confidence due to incoherence. All regimens were associated with approximately 30% increased probability of achieving HbA1c target, 1 kg greater weight gain, and a borderline increase in the risk of severe hypoglycaemia. Insulin doses were slightly higher with basal-bolus and biphasic regimens. Quality-of-life data were limited. Subgroup analyses for insulin initiation and intensification yielded consistent results. CONCLUSIONS/INTERPRETATION: Complex insulin regimens provide modest glycaemic benefits over basal insulin but are associated with greater weight gain and a suggested higher risk of hypoglycaemia. These results are based on evidence of moderate confidence. These trade-offs support the need for individualised regimen selection, informed by clinical context, patient preferences and treatment goals. TRIAL REGISTRATION: PROSPERO registration no. CRD42020181473. FUNDING: This research was supported by the Committee for the Development of Higher Education Personnel (CAPES) and the Hospital de Clínicas de Porto Alegre - FIPE HCPA.
引用
- Bertuol VC, Iorra F, Vieceli T, et al. Effects of insulin regimens for type 2 diabetes mellitus: a systematic review and network meta-analysis. Diabetologia. 2025. PMID: 41436667. doi:10.1007/s00125-025-06633-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。